Search filters

Filters
Clear All

Phase

  • 5
  • 12
  • 14
  • 18
  • 6
  • 74
  • 62
  • 74

Found 74 Muscular Dystrophy trials

A listing of Muscular Dystrophy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)
55 years - 90 years
All genders
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
 UPCC 35217: A Phase 1B/2  Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
99 years or below
All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
99 years or below
All genders
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
99 years or below
All genders
The purpose of the proposed study is to explore the nature of the codes that are present in the primary motor cortex. All complex actions involves the contraction of multiple muscles, the timing and intensity of which is precisely modulated. The traditional view of this process is that an abstract …
 Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank
18 years - 90 years
All genders
You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.
 An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Major Depressive Disorder
99 years or below
All genders
Phase 3
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder (MDD). Eligible subjects must have completed a prior MDD study with AXS-05 (AXS-05-301 or AXS-05-MDD-301) immediately prior to enrollment in this study.
 Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors
99 years or below
All genders
Phase 2
Since 2006, there has been a 50% increase in the number of adults added to the heart transplant waitlist in the US. Yet the persistent organ donor shortage has led to only a 25% increase in the number of transplants, and a 25% increase in the number of patients removed …
 Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites
99 years or below
All genders
Phase 3
This study is designed to evaluate the effects of Albutein 20% infusion on long-term survival (1-year transplant-free) in liver cirrhosis compared to the Standard Medical Treatment (SMT).
99 years or below
All genders
In the past, clinical trials on cutaneous lupus erythematosus (CLE) have not used patient-reported outcome measures to evaluate treatment efficacy; however, recent studies with small numbers of patients with CLE have compared questionnaires before and after treatment. Overall, there is little data available on changes in patient-reported outcome measures in …
99 years or below
All genders
Phase 2
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and compensated cirrhosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …